Emmaus Life Sciences, Inc. Net Income Loss

• Emmaus Life Sciences, Inc. showed a decrease of -16.1% in Net Income Loss from 2024 to 2025.
• This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2011 to 2025), Emmaus Life Sciences, Inc.'s Net Income Loss has grown by 15.5%.
• Historical annual values: Fiscal year 2025: -$7.49 million | Fiscal year 2024: -$6.45 million | Fiscal year 2023: -$3.73 million | Fiscal year 2022: -$10.63 million | Fiscal year 2021: -$15.95 million | Fiscal year 2020: $1.35 million | Fiscal year 2019: -$54.84 million | Fiscal year 2018: -$72.59 million | Fiscal year 2018: -$9.60 million | Fiscal year 2017: -$7.11 million | Fiscal year 2016: -$5.94 million | Fiscal year 2015: -$3.38 million | Fiscal year 2014: -$2.66 million | Fiscal year 2013: -$10.91 million | Fiscal year 2012: -$3.41 million | Fiscal year 2011: -$8.87 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026